DGIdb - SLC18A2 Gene Record

SLC18A2 6571 Druggable Genome

Alternate Names:

6571
SOLUTE CARRIER FAMILY 18 MEMBER A2
SLC18A2
SVAT
SVMT
VAT2
VMAT2
193001
10935
ENSG00000165646
OTTHUMG00000019121
Q05940
SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940]
VMAT2_HUMAN
SOLUTE CARRIER FAMILY 18 MEMBER 2
SYNAPTIC VESICLE AMINE TRANSPORTER
MONOAMINE TRANSPORTER
Vesicular amine transporter 2
Synaptic vesicular amine transporter
PA325
T48873
PKDYS2

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Target Main Class	Transporters
Target Subclass	SLC
Transmembrane Helix Count	12
Target Subclass	SLC18
Target Subclass	MFS
Target Class	Transporters
Target Subclass	TC:2.A.1.2.29
Gene Biotype	PROTEIN_CODING

(5 More Sources)

Gene Categories: Category Details

TRANSPORTER
DRUGGABLE GENOME

Publications:

Biezonski et al., 2010, Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity., J. Neurochem.
Hansen et al., 2002, Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity., J. Pharmacol. Exp. Ther.
Horton et al., 2011, meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release., J. Pharmacol. Exp. Ther.
Yasumoto et al., 2009, Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2., Neurosci. Lett.
Fleckenstein et al., 2007, New insights into the mechanism of action of amphetamines., Annu. Rev. Pharmacol. Toxicol.
Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
Sulzer et al., 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport., J. Neurosci.
Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol
Mandela et al., Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles., Neurochem. Int.
Naudon et al., 1995, Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex., Synapse
Erickson et al., 1992, Expression cloning of a reserpine-sensitive vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.
Sievert et al., 2007, Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels., Anal. Biochem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
SCHLAGEL et al., 1957, Rauwolfia hypotension. II. Action of the alseroxylon alkaloids and epinephrine on the carotid pressoreceptors., J Am Pharm Assoc Am Pharm Assoc
FORD et al., 1958, Rauwolfia toxicity in the treatment of hypertension; comparative toxicity of reserpine and alseroxylon., Postgrad Med
Loeffler et al., 1979, Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay., J Pharm Sci
Fulton et al., 1976, Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines., Fed. Proc.
Wimalasena, 2011, Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry., Med Res Rev
Kim et al., 2009, Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells., J. Neurosci.
Goland et al., 2009, 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls., J. Nucl. Med.
Zheng et al., 2006, Vesicular monoamine transporter 2: role as a novel target for drug development., AAPS J
Gros et al., 2010, Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter., J. Biol. Chem.
Eiden et al., 2011, VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse., Ann. N. Y. Acad. Sci.
Teng et al., 1998, Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine., J. Neurochem.
Heal et al., 2013, Amphetamine, past and present--a pharmacological and clinical perspective., J. Psychopharmacol. (Oxford)

TETRABENAZINE SLC18A2

Interaction Score: 10.85

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name tetrabenazine,Nitoman

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
20135628 19571144 19223416 17233532 11752352 20007701

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
LOBELINE SLC18A2

Interaction Score: 6.51

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name Lobeline

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
VALBENAZINE TOSYLATE SLC18A2

Interaction Score: 6.51

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name NBI-98854

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
DESERPIDINE SLC18A2

Interaction Score: 5.69

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
574544 20176067 8525459 1438304 17559790 11134

Sources:
ChemblInteractions
ALSEROXYLON SLC18A2

Interaction Score: 4.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
13505370 13438725 17016423 17139284 11752352

Sources:
TdgClinicalTrial TEND TTD
ALKAVERVIR SLC18A2

Interaction Score: 3.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
DEXTROAMPHETAMINE SLC18A2

Interaction Score: 2.17

Interaction Types & Directionality:

inducer (activating)

inhibitor (inhibitory)

Interaction Info:

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Novel drug target Established target

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
15955613 7751968

Sources:
TdgClinicalTrial ChemblInteractions
MIDOMAFETAMINE SLC18A2

Interaction Score: 1.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20002520 11861820

Sources:
TTD
RESERPINE SLC18A2

Interaction Score: 1.76

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
20176067 8525459 1438304 17559790 11752352 17016423 17139284 13438725 13505370

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
BENZPHETAMINE HYDROCHLORIDE SLC18A2

Interaction Score: 1.63

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
VALBENAZINE SLC18A2

Interaction Score: 1.63

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
DEUTETRABENAZINE SLC18A2

Interaction Score: 1.63

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
LISDEXAMFETAMINE DIMESYLATE SLC18A2

Interaction Score: 1.63

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name Vyvanse

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions
AMPHETAMINE SLC18A2

Interaction Score: 1.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
21272013 15955613 9648873 7751968 23539642

Sources:
TdgClinicalTrial
DEXTROAMPHETAMINE ADIPATE SLC18A2

Interaction Score: 1.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DEXTROAMPHETAMINE SULFATE SLC18A2

Interaction Score: 1.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
METHAMPHETAMINE SLC18A2

Interaction Score: 0.75

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
21177475 19429089 17209801 15955613 7751968

Sources:
TdgClinicalTrial
RESCINNAMINE SLC18A2

Interaction Score: 0.65

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BUPROPION SLC18A2

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22947179

Sources:
PharmGKB

Ensembl: ENSG00000165646
- Version: 101_38
Alternate Names:

SLC18A2 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: Q05940
- Version: January-2014
Alternate Names:

SLC18A2 Gene Symbol

Gene Info:

Target Class Transporters

Target Subclass TC:2.A.1.2.29

Publications:
TEND: Q05940
- Version: 01-August-2011
Alternate Names:

ENSG00000165646 Ensembl Gene Id

6571 Entrez Gene Id

SLC18A2 Gene Symbol

Gene Info:

Target Main Class Transporters

Target Subclass SLC

Transmembrane Helix Count 12

Publications:

RussLampel: ENSG00000165646

Version: 26-July-2011

Alternate Names:

SLC18A2 Display Id

SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940] Description

ENSG00000165646 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

PharmGKB: SLC18A2

Version: 18-August-2020

Alternate Names:

PA325 PharmGKB ID

Gene Info:

Publications:

Mas S et al., 2016, Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes., Pharmacogenomics J

Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol

HingoraniCasas: ENSG00000165646
- Version: 31-May-2017
Alternate Names:

ENSG00000165646 Gene Symbol

SLC18A2 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: SVMT
- Version: chembl_23
Alternate Names:

VMAT2 GENE_SYMBOL

SLC18A2 GENE_SYMBOL

Synaptic vesicular amine transporter UNIPROT

Gene Info:

Publications:
TTD: Synaptic vesicle amine transporter
- Version: 2020.06.01
Alternate Names:

SLC18A2 TTD Gene Abbreviation

T48873 TTD Target ID

Gene Info:

Publications:
Pharos: SLC18A2
- Version: 01-February-2022
Alternate Names:

Synaptic vesicular amine transporter Gene Name

Q05940 UniProt ID

Gene Info:

Gene Categories:

TRANSPORTER

Publications:

Novel drug target	Established target
Trial Name	tetrabenazine,Nitoman
Mechanism of Interaction	Synaptic vesicular amine transporter inhibitor

Mechanism of Interaction	Synaptic vesicular amine transporter inhibitor
Direct Interaction	yes

Trial Name	SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR
Novel drug target	Established target
Mechanism of Interaction	Synaptic vesicular amine transporter inhibitor

Trial Name	C105, levo-amphetamine sulfate
Novel drug target	Established target
Trial Name	SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Trial Name	low dose intravenous methamphetamine
Novel drug target	Established target

ENSG00000165646	Ensembl Gene Id
6571	Entrez Gene Id
SLC18A2	Gene Symbol

SLC18A2	Display Id
SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940]	Description
ENSG00000165646	Ensembl Gene Id

VMAT2	GENE_SYMBOL
SLC18A2	GENE_SYMBOL
Synaptic vesicular amine transporter	UNIPROT

Synaptic vesicular amine transporter	Gene Name
Q05940	UniProt ID

inducer (activating)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

SLC18A2 Gene Record

SLC18A2 6571 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name tetrabenazine,Nitoman Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs: 20135628 19571144 19223416 17233532 11752352 20007701

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name Lobeline

PMIDs: None found

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info: Trial Name NBI-98854 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes

PMIDs: 574544 20176067 8525459 1438304 17559790 11134

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 13505370 13438725 17016423 17139284 11752352

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inducer (activating) inhibitor (inhibitory)

Interaction Info: Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR Novel drug target Established target Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs: 15955613 7751968

Sources: TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 20002520 11861820

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes Trial Name -

PMIDs: 20176067 8525459 1438304 17559790 11752352 17016423 17139284 13438725 13505370

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes Trial Name Vyvanse

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name C105, levo-amphetamine sulfate Novel drug target Established target Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs: 21272013 15955613 9648873 7751968 23539642

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name low dose intravenous methamphetamine Novel drug target Established target

PMIDs: 21177475 19429089 17209801 15955613 7751968

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name tetrabenazine,Nitoman

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
20135628 19571144 19223416 17233532 11752352 20007701

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name Lobeline

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name NBI-98854

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
574544 20176067 8525459 1438304 17559790 11134

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
13505370 13438725 17016423 17139284 11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inducer (activating)

inhibitor (inhibitory)

Interaction Info:

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Novel drug target Established target

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
15955613 7751968

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
20002520 11861820

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
20176067 8525459 1438304 17559790 11752352 17016423 17139284 13438725 13505370

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name Vyvanse

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
21272013 15955613 9648873 7751968 23539642

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
21177475 19429089 17209801 15955613 7751968

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
22947179

Sources:
PharmGKB

Alternate Names:

SLC18A2 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

SLC18A2 Gene Symbol

Gene Info:

Target Class Transporters

Target Subclass TC:2.A.1.2.29

Alternate Names:

ENSG00000165646 Ensembl Gene Id

6571 Entrez Gene Id

SLC18A2 Gene Symbol

Gene Info:

Target Main Class Transporters

Target Subclass SLC

Transmembrane Helix Count 12

Alternate Names:

SLC18A2 Display Id

SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940] Description

ENSG00000165646 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME